A 28-year-old woman with mild persistent asthma is started on inhaled fluticasone propionate 110 µg twice daily. After 3 weeks, she reports persistent hoarseness and oral candidiasis. What is the most appropriate next step in management?

Explanation

## Management of Local Adverse Effects from Inhaled Corticosteroids ### Clinical Scenario Analysis The patient has developed two classic local adverse effects of inhaled corticosteroids (ICS): 1. **Hoarseness** — due to local deposition in the larynx and vocal cord irritation 2. **Oral candidiasis** — due to local immunosuppression and fungal overgrowth in the oropharynx These are NOT indications to discontinue therapy, but rather to optimize inhalation technique and hygiene. ### Correct Management Strategy **Key Point:** Local adverse effects of ICS are preventable through proper technique and post-inhalation hygiene, not by changing the drug or dose. **High-Yield:** The three-step prevention protocol for ICS-related oropharyngeal candidiasis: 1. Use a **spacer device** — reduces oropharyngeal deposition by 50–80% 2. **Rinse mouth** with water immediately after inhalation 3. Consider antifungal rinse (nystatin) if candidiasis persists despite above measures ### Why This Approach Works | Intervention | Mechanism | Efficacy | |---|---|---| | Spacer device | Reduces particle size impact; increases lung deposition; decreases oropharyngeal deposition | 50–80% reduction in local effects | | Mouth rinsing | Removes residual steroid particles from oropharynx | Prevents candida colonization | | Proper technique training | Ensures inhalation during inspiration; reduces swallowing | Reduces systemic and local exposure | **Clinical Pearl:** Hoarseness typically resolves within 1–2 weeks once proper technique is established; candidiasis may take 2–4 weeks to resolve even with preventive measures. **Mnemonic:** **SAM** — **S**pacer, **A**dvice (rinse mouth), **M**aintain dose. ### Why Dose or Drug Change Is Unnecessary The patient's asthma is well-controlled on the current dose (mild persistent asthma on low-dose ICS is appropriate). Local effects do not indicate inadequate disease control — they indicate inadequate inhalation technique. [cite:KD Tripathi 8e Ch 28]